Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 19 of 23
Feb 18, 2026Historically known for collaborating in drug development, Ionis Pharmaceuticals charted a new course by bringing two medicines to market alone in 2025. Industry analysts are recognizing the company's strategic pivot and anticipate further progress in 2026.
Daniel Cho
Feb 18, 2026In a significant development for the biopharmaceutical industry and consumer safety, Bayer has reached a proposed $7.25 billion settlement addressing claims that its weedkiller Roundup caused cancer. This settlement represents one of the largest in the industry related to product liability and could have wide-reaching implications for regulatory practices and corporate responsibility in chemical and pharmaceutical product management.
Jonathan Blake
Feb 17, 2026The fetal bovine serum shortage is posing significant supply chain challenges across the biopharma sector. This article analyzes the implications of the squeeze on drug prices and discusses mitigation strategies companies can adopt to reduce impact.
Dr. Alex Morgan
Feb 13, 2026As competition intensifies in the weight management sector, Eli Lilly has been ramping up manufacturing investments for orforglipron since early 2024 in anticipation of its approval. Concurrently, Novo Nordisk is expanding its presence by introducing its oral GLP-1 drug Wegovy beyond the U.S. market, signaling a strategic push to capture global demand.
Michael Torres
Feb 12, 2026As the biopharmaceutical industry continues to evolve rapidly, understanding the nuances of the job market and hiring landscape remains essential for professionals aiming to navigate this complex environment successfully. Insights from industry talent acquisition and recruiting experts reveal key trends that will inform career strategies in 2026.
Dr. Alex Morgan
Feb 12, 2026The departure of Paul Hudson from the CEO position at Sanofi highlights the challenges faced by major pharmaceutical companies in defining clear pathways for growth in a rapidly evolving market. The leadership change comes at a pivotal time as Sanofi reassesses its strategic priorities and pipeline prospects.
Jonathan Blake
Feb 11, 2026PharmaEssentia’s new manufacturing center in Puerto Rico represents a substantial move to shore up drug production capacity for the U.S. market. This investment points to broader trends in pharmaceutical supply chain resilience and regional manufacturing expansion.
Dr. Alex Morgan
Feb 11, 2026Evommune's innovative biologic drug EVO301 demonstrated successful outcomes in a placebo-controlled Phase 2a study for atopic dermatitis. By neutralizing specific inflammatory signaling proteins, it may offer a differentiated mechanism compared to the current market leader, Dupixent by Sanofi and Regeneron Pharmaceuticals.
Emily Carter
Feb 10, 2026The $2.4 billion deal positions Eli Lilly to leverage Orna's novel in vivo cell therapy platform, aiming to address autoimmune conditions by harnessing CAR T technology directly within the body. This acquisition reflects a broader pharma interest in cell therapies and personalized medicine.
Sophia Reynolds
Feb 9, 2026Genentech's workforce reductions have extended with the revelation of 141 more layoffs last year. This development reflects ongoing shifts in the biotech industry employment landscape, impacted by broader economic and strategic considerations within the sector.
Michael Torres
Feb 9, 2026Novo Nordisk, a leader in obesity drug development, initiated legal proceedings against wellness platform Hims & Hers for producing and selling an unauthorized, compounded version of its oral Wegovy pill. This dispute spotlights ongoing tensions in the pharmaceutical industry around patent rights, drug compounding, and market competition.
Emily Carter
Feb 8, 2026The recent proof-of-concept clinical trial results for brepocitinib mark a pivotal milestone for Roivant’s rare disease pipeline. Licensed from Pfizer, this dual JAK1 and TYK2 inhibitor demonstrated promising outcomes in cutaneous sarcoidosis, an area of high unmet medical need with no FDA-approved therapies, positioning the drug on a path toward pivotal testing and potential blockbuster status.
Daniel ChoMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.